Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Effectiveness of adjuvant trastuzumab in daily clinical practice
Authors:ID Matos, Erika (Author)
ID Zakotnik, Branko (Author)
ID Grašič-Kuhar, Cvetka (Author)
Files:.pdf PDF - Presentation file, download (549,44 KB)
MD5: 431EAD81FD4682BC6579E9AB034905B0
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice. Patients and methods. An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed. Results. Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021). Conclusions. The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
Keywords:breast cancer, trastuzumab, adjuvant, clinical practice
Publication status:Published
Publication version:Version of Record
Publication date:01.12.2014
Publisher:Association of Radiology and Oncology
Year of publishing:2014
Number of pages:str. 403-407, VII
Numbering:Vol. 48, no. 4
Source:Ljubljana
PID:20.500.12556/DiRROS-18662 New window
UDC:618.1-006
ISSN on article:1318-2099
DOI:10.2478/raon-2013-0081 New window
COBISS.SI-ID:1778043 New window
Copyright:by Authors
Publication date in DiRROS:11.04.2024
Views:109
Downloads:23
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:rak dojke, adjuvantno zdravljenje, klinična praksa, trastuzumab


Back